# Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma

> **NCT00365222** · PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 1 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00365222
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** IRB Study Closure
- **Last updated:** 2009-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00365222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00365222, "Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00365222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*